Staphylococcus aureus protein SAUGI acts as a uracil-DNA glycosylase inhibitor

Hao-Ching Wang1,2, Kai-Cheng Hsu3, Jinn-Moon Yang3,4,5, Mao-Lun Wu1, Tzu-Ping Ko1,6, Shen-Rong Lin3 and Andrew H.-J. Wang1,2,6,*

1Institute of Biological Chemistry, Academia Sinica, Taipei 115, Taiwan, 2Graduate Institute of Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan, 3Institute of Bioinformatics and Systems Biology, National Chiao Tung University, Hsinchu, 30050, Taiwan, 4Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, 30050, Taiwan, 5Center for Bioinformatics Research, National Chiao Tung University, Hsinchu, 30050, Taiwan and 6Core Facilities for Protein Structural Analysis, Academia Sinica, Taipei 115, Taiwan

Received June 28, 2013; Revised and Accepted September 30, 2013

ABSTRACT

DNA mimic proteins are unique factors that control the DNA binding activity of target proteins by directly occupying their DNA binding sites. The extremely divergent amino acid sequences of the DNA mimics make these proteins hard to predict, and although they are likely to be ubiquitous, to date, only a few have been reported and functionally analyzed. Here we used a bioinformatic approach to look for potential DNA mimic proteins among previously reported protein structures. From ~14 candidates, we selected the Staphylococcus conserved hypothetical protein SSP0047, and used proteomic and structural approaches to show that it is a novel DNA mimic protein. In Staphylococcus aureus, we found that this protein acts as a uracil-DNA glycosylase inhibitor, and therefore named it S. aureus uracil-DNA glycosylase inhibitor (SAUGI). We also determined and analyzed the complex structure of SAUGI and S. aureus uracil-DNA glycosylase (SAUDG). Subsequent BIAcore studies further showed that SAUGI has a high binding affinity to both S. aureus and human UDG. The two uracil-DNA glycosylase inhibitors (UGI and p56) previously known to science were both found in Bacillus phages, and this is the first report of a bacterial DNA mimic that may regulate SAUDG’s functional roles in DNA repair and host defense.

INTRODUCTION

Research in the past decade has revealed several examples of regulatory proteins that mimic DNA. These proteins use negatively charged amino acids to imitate the charge distribution of DNA and thus prevent DNA from binding to its original target protein by direct competition (1,2). DNA mimic proteins can be found in virus, bacteria and eukaryotic cells, and they are involved in many important control mechanisms, including DNA repair, restriction, transcriptional control and DNA packaging (2). All of these observations suggest that DNA mimic proteins are essential to living cells, and the discovery of new mimics is potentially important in many areas of research. However, only a few DNA mimic proteins (<20) have so far been reported. The reason is that these proteins are hard to identify because their amino acid sequences and protein structures are extremely divergent (2).

We have been developing bioinformatic approaches to identify new DNA mimics, and here we found several candidates. One of these, the Staphylococcus conserved protein SSP0047, was selected for further study. In this report, we show that SSP0047 (or SAUGI; for Staphylococcus aureus uracil-DNA glycosylase inhibitor) acts as a uracil-DNA glycosylase inhibitor that breaks the uracil-removing activity of S. aureus uracil-DNA glycosylase (SAUDG). We also determined the structure of the SAUGI/SAUDG complex, and used surface plasmon resonance (BIAcore) to show that SAUGI has a high binding affinity to UDG.

Functionally, UDGs remove the uracils in DNA that result from the spontaneous deamination of cytosine or the incorporation of dUTP during replication (3,4). To date, only two uracil-DNA glycosylase inhibitors (UGI and p56) have been identified. One of these, phage PBS2 UGI, forms a tight and physiologically irreversible complex with a variety of UDG proteins in 1:1 molar stoichiometry (4–8). The other protein, p56, was identified in the Bacillus phage φ 29. Although its dimeric structure is different from the monomeric UGI, p56 has been shown...
to inhibit UDG’s activity as well (9–12). SAUGI is therefore the third uracil-DNA glycosylase inhibitor that has been identified, and the first in a species other than bacterial phage.

**MATERIALS AND METHODS**

**Bioinformatic search for possible DNA mimic candidates in the protein structure database**

To function as a DNA mimic, a protein must have two critical properties: a DNA-like arrangement of negative charges on its surface and an appropriate structural conformation (2,13). Here, we used these two properties to search for potential DNA mimic proteins in the Protein Data Bank (PDB). First, we used the 12 known DNA mimic proteins listed in Supplementary Table S1 (5–8,14–24) as starting queries to search on the DALI server (25) for proteins with loosely similar structures, with values above eight indicating good structural superimposition. Next, the list of candidate proteins was further reduced by applying additional constraints that were deduced from all 12 of the published DNA mimic proteins (Supplementary Table S1): (i) a protein size of <200 amino acids; (ii) a total of at least 10 aspartic acid and/or glutamic acid residues on the protein surface; and (iii) a negative charge on at least 10% of the surface residues. Finally, 14 proteins were considered potential DNA mimic proteins based on the similarity of negative charge distributions to the original query proteins (Supplementary Figure S1 and Supplementary Table S2).

**Preparation and purification of recombinant SAUGI and SAUDG**

For N-terminal His$_{10}$-tagged SAUGI, the full-length SAUGI gene (NCBI sequence ID: AAL26663.1, amino-acid residues 1–112) with the stop codon was ligated into pET16b expression vector (Novagen). For C-terminal His$_8$-tagged SAUDG, the full-length SAUDG gene (NCBI sequence ID: YP_040034.1, amino-acid residues 1–218) and human UDG gene (NCBI sequence ID and PDB: 1SSP_E, amino-acid residues 1–223) without the stop codon were ligated into pET21b expression vector (Novagen). All vectors were transformed into *Escherichia coli* BL21 (DE3), and after the addition of 1 mM isopropyl-$\beta$-thiogalactopyranoside (IPTG), the recombinant proteins were expressed for 16 h at 16°C. Soluble proteins were purified by immobilized metal-ion chromatography with a Ni-NTA column, followed by gel filtration using Superdex 75 (GE Healthcare).

For tag-free SAUGI, a pET21b expression vector containing the full-length SAUGI gene with the stop codon was transformed into *E. coli* BL21 (DE3). After addition of 1 mM IPTG, the recombinant SAUGI protein without any tag was expressed for 16 h at 16°C. Soluble SAUGI was purified by Q anion exchange chromatography (GE Healthcare) with a gradient of 0–0.75 M NaCl in 20 mM Tris, pH 7.4, buffer. SAUGI’s purity was further improved using gel filtration on a Superdex 75 column.

**His-pulldown assays to identify proteins that interact with SAUGI**

For the first His-pulldown assay, the soluble proteins extracted from *S. aureus* (200 μg) were mixed with purified N-terminal His$_{10}$-tagged SAUGI (1 mg). The reaction mixture was adjusted to a final volume of 1 ml in a binding buffer of 1× phosphate buffered saline with 20 mM imidazole, and incubated for 16 h at 4°C. Incubation then continued with Ni-NTA beads (50 μl) for another 1 h. After incubation, the beads were washed with 5 ml of the same binding buffer. Proteins bound to the beads were then eluted by the addition of buffer containing 500 mM imidazole and resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. Protein bands of interest were excised from the gels and digested in-gel by trypsin. LC-nanoESI-MS/MS and the search program MASCOT were used to identify the proteins. In MASCOT, the selected variable modifications were methionine oxidation and cysteine carboxymethylation. Significant hits (as defined by Mascot probability analysis) were regarded as positive identification. In another His-pulldown assay to confirm the interaction between SAUGI and SAUDG, 3 μM purified C-terminal His$_8$-tagged SAUDG was mixed with 1 μM untagged SAUGI. Subsequent steps in this assay were the same as described above.

**Gel filtration to determine the native molecular weights of target proteins**

A Superdex 75 10/300 gel filtration column (GE Healthcare) was used to estimate the approximate molecular weights (MWs) of SAUGI and SAUDG, as well as the SAUGI/SAUDG complex. The buffer used in this assay was 30 mM Tris–HCl, pH 7.4, 100 mM NaCl, 5% glycerol, 1 mM EDTA and 1 mM Dithiothreitol (DTT). Gel filtration standard proteins [ovalbumin (43 kDa), carbonic anhydrase (29 kDa), RNase A (13.7 kDa) and aprotinin (6.5 kDa)] were used to create a calibration curve for protein MWs on the same gel filtration column. For each protein, the logarithm of MW was plotted against $K_a$, which was calculated as follows: $K_a = (V_e–V_o)/(V_t–V_o)$, where $V_e$ is the elution volume, $V_o$ is the column void volume using blue dextran 2000 and $V_t$ is the total column bed volume (24 ml for the Superdex 75 10/300 gel filtration column).

**Crystallization, data collection and structure determination of SAUDG and the SAUDG/SAUGI complex**

For SAUDG crystallization, 2 μl of purified C-terminal His$_8$-tagged SAUDG solution (16 mg/ml; 20 mM Tris, pH 8.0, and 100 mM NaCl) were mixed with 2 μl of a reservoir containing 0.1 M Hepes sodium, pH 7.5, 10% 2-propanol and 18% PEG4000 as a precipitant.
For crystallization of the SAUDG/SAUGI complex, 1 mg of SAUGI and 2.5 mg of C-terminal His6-tagged SAUDG were mixed in 100 μl of complex buffer (30 mM Tris–HCl, pH 7.4, 5% glycerol, 100 mM NaCl, 1 mM EDTA and 1 mM DTT) at room temperature (RT) for 1 h. A Superdex 75 gel filtration column was then used to separate the complex from the uncomplexed monomers. Subsequently, 2 μl of the complex solution (20 mg/ml) were mixed with 2 μl of a reservoir containing 0.1 M sodium Hepes, pH 7.2, and 15% PEG20000 as a precipitant. Equilibration with the reservoir was achieved by the sitting drop method. Before flash cooling, ethylene glycol at a final concentration of 15% was added as a cryoprotectant for both the SAUDG and SAUDG/SAUGI complex crystals.

Native X-ray diffraction data were collected from the SAUDG and SAUDG/SAUGI complex crystals on beamline 13B at the National Synchrotron Radiation Research Center in Hsinchu, Taiwan. The data were processed using HKL2000 (26). Molecular replacement calculations were performed by the program Molrep (27). For SAUDG, the crystal structure of *Vibrio cholerae* uracil-DNA glycosylase (PDB number: 2JHQ) was used as a search model, and for the SAUDG/SAUGI complex, a search model was constructed by replacing the UGI in the crystal structure of *E. coli* UDG/UGI (PDB number: 2UGI) with the *Staphylococcus saprophyticus* hypothetical protein SSP0047 (PDB number: 2KCD). Both initial maps were produced after preliminary refinement using Refmac (28), and the programs Buccaneer (29), Coot (30) and Refmac (28) were used in the subsequent model building and refinement. Model bias was removed by simulated annealing and checking against composite maps calculated by CNS (31) using 20 different models. Statistics for the data collection and refinement are shown in Table 1.

**Table 1.** Data collection and refinement statistics of SAUDG and SAUGI/SAUDG crystals

<table>
<thead>
<tr>
<th></th>
<th>SAUDG</th>
<th>SAUGI/SAUDG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wave length (Å)</td>
<td>1.00000</td>
<td>1.00000</td>
</tr>
<tr>
<td>Space group</td>
<td>P2₁</td>
<td>P2₁2₁2₁</td>
</tr>
<tr>
<td>Unit cell a, b, c (Å)</td>
<td>56.4, 79.5, 62.6</td>
<td>51.6, 86.4, 88.5</td>
</tr>
<tr>
<td>β (°)</td>
<td>112.1</td>
<td></td>
</tr>
<tr>
<td>Resolution (Å)</td>
<td>50.1.48 (1.53–1.48)</td>
<td>25–2.2 (2.28–2.20)</td>
</tr>
<tr>
<td>Unique reflections</td>
<td>82029</td>
<td>20216 (1636)</td>
</tr>
<tr>
<td>Redundancy</td>
<td>4.3 (4.1)</td>
<td>9.1 (6.8)</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>96.6 (94.7)</td>
<td>97.6 (80.7)</td>
</tr>
<tr>
<td>I/Completeness (%)</td>
<td>7.7 (2.6)</td>
<td>97.6 (80.7)</td>
</tr>
<tr>
<td>Unique reflections</td>
<td>82029</td>
<td>20216 (1636)</td>
</tr>
<tr>
<td>Redundancy</td>
<td>4.3 (4.1)</td>
<td>9.1 (6.8)</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>96.6 (94.7)</td>
<td>97.6 (80.7)</td>
</tr>
<tr>
<td>I/Completeness (%)</td>
<td>7.7 (2.6)</td>
<td>97.6 (80.7)</td>
</tr>
<tr>
<td>Mean B value/no of atom</td>
<td>19.4/4019</td>
<td>14.0/2970</td>
</tr>
<tr>
<td>Most favored (%)</td>
<td>96.73</td>
<td>95.34</td>
</tr>
<tr>
<td>Allowed (%)</td>
<td>2.80</td>
<td>3.73</td>
</tr>
<tr>
<td>Outliers (%)</td>
<td>0.47</td>
<td>0.93</td>
</tr>
</tbody>
</table>

The PyMOL program (32) was used for the structural analyses and also for figure production.

**Determination of the binding affinities between UGIs and UDGs**

The binding affinities of SAUGI and UGI to SAUDG and human UDG were determined by surface plasmon resonance using a BIAcore T200 (GE Healthcare) according to the protocols provided by the manufacturer. Briefly, the anti-His antibody was immobilized on the CM5 chip surface using the standard amine coupling method. The C-terminal His6-tagged UDG was then immobilized on the CM5 chip surface by binding to the anti-His antibody. Typically 20–30 response units were immobilized on the individual flow cells of the sensor chip. Next, SAUGI or UGI in 10 mM Hepes, 150 mM NaCl and 0.05% v/v Surfactant P20 was injected for 1 min at a flow rate of 30 μl/min. Association (ka) and dissociation (kd) kinetic constants were calculated by BIAevaluation 3.1 software using a simple 1:1 Langmuir model. The equilibrium dissociation constant KD values were calculated by the equation KD = kd/ka.

**Determination of SAUGI's ability to inhibit SAUDG activity**

The methods used here to measure the uracil removing activity of SAUDG were modified from procedures described in previous reports (9,33). For the single-stranded DNA (ssDNA) activity of SAUDG, a 40-mer Hex-labeled oligodeoxynucleotide containing a single uracil (ssDNA19U; 5’-Hex-GTAAAACGACGGCCAG TGUATTCGAGCTCGGTACC CGGGG-3’) was used as the DNA substrate. For SAUDG’s double-stranded DNA (dsDNA) activity, 40-mer dsDNA fragments were prepared by mixing equal volumes and concentrations of ssDNA19U and its no-uracil complementary oligonucleotide (5’-FAM-CCCCGGGTACCGAGCTCGAAGGCA CTGGCCGTCGTTTTAC-3’), incubating the reaction mixtures at 95°C for 5 min, and then lowering the temperature to RT for another 30 min. For each reaction, different amounts of purified recombinant SAUGI were mixed with C-terminal His6-tagged SAUDG. The reaction mixtures were adjusted to a volume of 9 μl in reaction buffer (for the ssDNA reaction: 20 mM Tris–HCl, pH 8.0, 1 mM DTT, 1 mM EDTA; for the dsDNA reaction: 50 mM potassium acetate, 20 mM Tris–acetate, pH 7.9, 10 mM magnesium acetate and 1 mM DTT) and preincubated at 37°C for 15 min. Subsequently, 1 μl of reaction buffer containing the respective ssDNA and dsDNA substrates was added to a final concentration of 0.5 μM, and the incubation continued for 15 min. Lastly, to cleave the apurinic sites in the ssDNA, NaOH was added to a final concentration of 0.2 M and allowed to react at 90°C for 30 min, while apurinic-apyrimidinic (AP) endonuclease I (4 units, New England Biolabs) was added and allowed to react at 37°C for 30 min to cleave the apurinic sites in the dsDNA. The dsDNA reaction was terminated by raising the temperature to 95°C for 5 min. The ssDNA and dsDNA reaction products were then mixed with 2× sample loading buffer (95%
formamide, 20 mM EDTA, 1 mg/ml bromophenol blue) and run on a 20% polyacrylamide gel (0.5× Tris-borate-EDTA buffer, 8 M urea). The results were visualized using ultraviolet light.

RESULTS
Bioinformatic search for DNA mimic candidates from the PDB

In total, 14 potential DNA mimic proteins were identified based on the properties of the known DNA mimic proteins. The structures and negative charge distributions of these proteins are all similar to their respective query proteins (Supplementary Figure S1 and Supplementary Table S2). Among these candidates, the *Staphylococcus* hypothetical protein SSP0047 (PDB number: 2KCD) is similar to the uracil-DNA glycosylase inhibitor from phage PBS2 (UGI; PDB number: 1UGI) with a Z-score of 5.8 and RMSD of 2.9 Å. Although there are several other candidates with higher Z-scores and/or lower RMSD scores, we selected SSP0047 for further study because the negative charge distribution on its surface bears the highest similarity to its original query protein (Supplementary Figure S1). Interestingly, although the protein fold and charge distributions of SSP0047 and UGI are similar, their amino acid sequences show only a weak homology (Supplementary Figure S2). The function of this protein had not been identified before, but its nuclear magnetic resonance (NMR) structure was determined by Northeast Structural Genomics Consortium (34) and released in 2009. A comparison of the distances between the carboxyl groups on the side chains of SSP0047 and the phosphate groups on B-form DNA suggests that this protein is a DNA mimic (Supplementary Figure S3). Taken together, these data suggest that SSP0047 may act as a UGI-like uracil-DNA glycosylase inhibitor. Since the SSP0047 protein is conserved in different *Staphylococcus* spp, in the following experiments we decided to focus on the SSP0047 homolog from the important human pathogen *S. aureus*. The protein is subsequently referred to as SAUGI.

The interaction between SAUGI and SAUDG

A His pulldown assay was used to identify possible interacting partners of SAUGI. In this assay, SAUGI was used as bait and proteins extracted from *S. aureus* were used as prey. The result showed many *S. aureus* proteins being pulled down by SAUGI (Supplementary Figure S4). Six protein bands were selected and identified using mass spectrometry. Interestingly, within these bands there were at least 8 DNA binding proteins, including DNA topoisomerase IV A subunit (GyrA/ParC), catabolite control protein A (CcpA), phosphosugar binding transcriptional regulator (RpiR family), accessory gene regulator A (agrA), two-component system response regulator (WalR/VicR), GTP-sensing transcriptional pleiotropic repressor (CodY), DNA damage-inducible repressor (LexA) and SAUDG (Supplementary Table S3). Since the protein folding of SAUGI is similar to that of UGI (Supplementary Figure S2), we hypothesized that SAUDG is likely a good target for SAUGI. We therefore further investigated the interaction between these two proteins.

First, the interaction between SAUGI and SAUDG was reconfirmed by another His pulldown assay, which showed that SAUGI without any tag could be pulled down by C-terminal His<sub>6</sub>-tagged SAUDG (Figure 1).

![Figure 1](#)

The SAUGI-SAUDG interaction confirmed by His-pulldown. In this assay, SAUGI without any tag was used as prey and C-terminal His<sub>6</sub>-tagged SAUDG was used as bait. The result showed that SAUGI was pulled down by C-terminal His<sub>6</sub>-tagged SAUDG.

<table>
<thead>
<tr>
<th></th>
<th>Gel filtration</th>
<th>Analytical ultracentrifugation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Theoretical MW&lt;sup&gt;a&lt;/sup&gt; (kDa)</td>
<td>Calculated MW (kDa)</td>
</tr>
<tr>
<td>SAUGI monomer</td>
<td>14.4</td>
<td>21.2</td>
</tr>
<tr>
<td>SAUDG monomer</td>
<td>26.0</td>
<td>25.3</td>
</tr>
<tr>
<td>SAUGI/SAUDG</td>
<td>40.4</td>
<td>36.7</td>
</tr>
</tbody>
</table>

<sup>a</sup>The theoretical MW is based on the amino acid sequence.
<sup>b</sup>The program SEDFIT (http://www.analyticalultracentrifugation.com) was used to calculate the MWs by using sedimentation coefficients from each protein peak.
<sup>c</sup>HYDROPRO (35) predicted the S values based on the atomic coordinates reported in this study.
Gel filtration chromatography gave calculated MWs for SAUDG and the SAUGI/SAUDG complex that were close to the respective theoretical MWs of the SAUDG monomer and the monomer-to-monomer complex (Supplementary Figure S5A and Table 2). The calculated MW of SAUGI was \( \sim 50\% \) greater than its predicted monomer weight, but this was probably due to nonspecific interactions between SAUGI and the column material (Supplementary Figure S5A and Table 2). Analytical ultracentrifugation results for SAUGI and SAUDG were both close to the theoretical monomer values, while the calculated MW for the complex was within 10\% of its theoretical MW (Supplementary Figure S5B and Table 2). Taken together, these results suggest that SAUGI forms a monomer-to-monomer complex with SAUDG that corresponds to the previously reported UGI/UDG complex.

The crystal structures of SAUDG and SAUGI/SAUDG

SAUDG has a conserved fold that is similar to the reported UDG structures from other species. Structural alignment shows that the Leu184 of SAUDG corresponds to the protruding residue Leu191 of \( E. \ coli \) UDG, Phe191 of \( B. \ subtilis \) UDG and Leu272 of human UDG (Supplementary Figure S6A). The side chains of these residues insert into DNA’s minor groove to replace the flipped-out uracil, and they are crucial for the formation of a stable complex between UDG and its respective substrate (36,37). Additionally, three loops [4-Pro, Gly-Ser and Leu272 loops; (37)] that accomplish compression of the phosphates in the human UDG/DNA complex are also conserved in these UDG structures (Supplementary Figure S6A). Structural alignment of SAUDG with the human UDG/DNA complex further suggested the probable location of DNA binding region in SAUDG (Supplementary Figure S6B).

The complex crystal structure of SAUGI/SAUDG is shown in Figure 2A. SAUGI binds directly to the DNA binding region of SAUDG. In the SAUGI/SAUDG interface, at least 20 water molecules were observed. These presumably form a network of hydrogen bonds between the proteins, and so far 12 direct hydrogen bonds and 8 water-mediated bonds have been found (Figure 2B and Supplementary Table S4). In addition, the side chain of the protruding residue Leu184 in SAUDG is surrounded by the side chains of Ile35, Phe69, Leu71, Ile83 and Met89 in SAUGI, and this provides hydrophobic interactions that further stabilize the complex (Figure 2C). Adjacent to this hydrophobic region, SAUDG also has Pro82 and Pro183 posed against the side chains of Thr55 and Tyr67 in SAUGI, which contributes further to the nonpolar interactions (Figure 2D). Near the center of the interface, there are potential van der Waals interactions between the

Figure 2. Crystal structures of the SAUGI/SAUDG complex and SAUDG. (A) Ribbon diagrams of the SAUGI/SAUDG complex and SAUDG. The \( \alpha \)-helices and \( \beta \)-strands are, respectively, colored red and yellow in SAUDG and cyan and magenta in SAUGI. The secondary structural elements and the amino acid sequences of SAUGI and SAUDG can be found in Supplementary Figure S7. (B) The SAUGI/SAUDG interface. In the magnified inset, selected residues of SAUGI and SAUDG are labeled in black and red, respectively. The pink dashed lines represent hydrogen bonds. Four of the residues on the SAUGI strand \( \beta \)-1, Glu24, Cys25, Ser27 and Glu29, are hydrogen-bonded to SAUDG, which suggests the importance of strand \( \beta \)-1 for SAUGI’s binding affinity. (C–E) Other important interactions that contribute to the binding between SAUGI (cyan) and SAUDG (green). The SAUGI side chains are colored red, while those of SAUDG are orange.
Conformational changes in SAUDG and SAUGI on complex formation

The binding between SAUGI and SAUDG did not induce any large conformational changes in SAUDG (Figure 3A; the RMSD fit is 0.345 Å). The most significant conformational change was found in the loop region formed by residues 75–80 (Figure 3B), which corresponds to the phosphate-compressing 4-Pro loop in the human UDG/DNA complex. The Lys79 side chain on this loop moves forward and forms a hydrogen bond with the Asp59 side chain of SAUGI (Supplementary Table S4). The side chain orientations of Leu184 and Arg85 on SAUDG were also affected by their interactions with the SAUGI residues (Figure 3C and D).

For SAUGI, an RMSD fit of 1.22 Å was calculated between the unbound SSP0047 (as determined by NMR) and SAUDG-bound SAUGI (as determined by radiographic crystallography). Structural differences were seen in two loop regions (Supplementary Figure S9; residues 41–49; 73–75). However, it is not clear whether these differences were due to the binding to SAUDG, or to the different determination methods (i.e. NMR versus radiography).

The binding affinity of SAUGI and SAUDG

The binding affinities between various uracil-DNA glycosylase inhibitors and UDGs were measured using surface plasmon resonance (BIAcore) (Supplementary Figure S10 and Table 3). The results showed that SAUGI and SAUDG have rapid association and slow disassociation rates. This turns out a high equilibrium dissociation constant (KD = 1 nM) and implies SAUGI is a strong inhibitor of SAUDG. Interestingly, SAUGI also binds to human UDG with a high equilibrium dissociation constant (KD = 2.5 nM), a relatively slow association rate and the same slow disassociation rate. Moreover, for bacterial SAUDG, the binding affinity of UGI is about twice that of SAUGI, while for human UDG, the binding affinity of UGI is 12–13 times greater than SAUGI's.

SAUGI inhibits the uracil-removing activity of SAUDG

To further confirm that SAUGI acts as a uracil-DNA glycosylase inhibitor, the SAUDG activity was determined by an in vitro glycosylase cleavage assay in the presence or absence of SAUGI. In the absence of SAUGI, SAUDG removed the uracil from both ssDNA and dsDNA, as

Table 3. The binding affinities of uracil-DNA glycosylase inhibitors and UDGs

<table>
<thead>
<tr>
<th>UGI</th>
<th>ka (1/Ms)</th>
<th>kd (1/s)</th>
<th>KD (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAUGI to</td>
<td>2472.386 ± 1636</td>
<td>0.00296 ± 0.00010</td>
<td>1.198 ± 0.029</td>
</tr>
<tr>
<td>SAUDG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phage UGI to</td>
<td>8904.442 ± 419216</td>
<td>0.00610 ± 0.00068</td>
<td>0.685 ± 0.080</td>
</tr>
<tr>
<td>SAUDG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SAUGI to</td>
<td>495.685 ± 22047</td>
<td>0.00124 ± 0.00001</td>
<td>2.509 ± 0.088</td>
</tr>
<tr>
<td>human UDG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phage UGI to</td>
<td>6315.673 ± 187973</td>
<td>0.00119 ± 0.00010</td>
<td>0.189 ± 0.021</td>
</tr>
<tr>
<td>human UDG</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
shown by the cleavage at the resulting apyrimidinic site when treated with heat and alkali (ssDNA) or with AP endonuclease (dsDNA) (Figure 4A lane 2 and Figure 4B lane 3). In contrast, the amounts of cleaved product were progressively reduced by the addition of increasing quantities of SAUGI (Figure 4A and B). SAUDG activity was completely inhibited when the molar ratio of SAUGI to SAUDG reached 1:1 for the ssDNA assay and 2:1 for the dsDNA assay. The slight difference in the inhibiting effect of SAUGI on the ssDNA and dsDNA uracil-removing activity by SAUDG may be due to the different reaction buffers used.

DISCUSSION
The two previously known uracil-DNA glycosylase inhibitors are well-studied DNA mimic proteins that specifically inhibit the activity of UDGs. One of these mimics, phage...
PBS2 UGI, contains a DNA-like surface that binds to the DNA binding region of UDG and thus blocks its uracil-removing activity (5–8,38). This serves to protect the special genomic DNA of PBS2, which is unusual in that it incorporates uracil residues instead of thymine residues (39). The other uracil-DNA glycosylase inhibitor, p56, was identified from Bacillus phage φ 29 (9–12).

Interestingly, despite its similar function, the dimeric structure of p56 is different from that of the monomeric UGI (10). This p56 has later been shown to form a complex with both Bacillus UDG and herpes simplex virus (HSV) UDG (11,12). Unlike phage PBS2, the genomic DNA of φ 29 does not contain uracil residues, but Serrano-Heras (2006) hypothesized that p56 might

Figure 5. A structural comparison of SAUGI, UGI, p56 and their respective complexes with UDG. (A) The known uracil-DNA glycosylase inhibitors. The α-helices and β-strands are, respectively, colored red and yellow in SAUGI, UGI and one molecule of the p56 dimer, and cyan and magenta in the other p56 molecule. (B) A comparison of the UDG complexes with SAUGI, UGI, p56 and DNA. The uracil-DNA glycosylase inhibitors and the UDGs are, respectively, colored cyan and green. The protruding residues from the UDGs are shown as yellow sticks. (C) Details of the hydrophobic binding pockets in the interacting regions of the three uracil-DNA glycosylase inhibitors. Residues of the protein inhibitors and UDGs are shown as red and orange sticks, respectively.
knock out the host-encoded UDG base-excision repair system because this UDG activity could still be harmful to phage replication if uracil residues occur in the replicative intermediates (40). This hypothesis was recently confirmed (41).

In terms of the protein folding and charge distribution, SAUGI is a DNA mimic that resembles UGI rather than p56 (Figure 5A). Figure 5B and C further shows how SAUGI, UGI and p56 all share a conserved UDG binding strategy, which involves targeting their respective UDG’s protruding residue (i.e. SAUDG Leu184, E. coli UDG Leu191 and B. subtilis UDG Phe191; see Supplementary Figure S6A) by means of a hydrophobic pocket. Interestingly, unlike the conformational changes seen in the loops and β-zippers of human UDG when it binds to DNA (37), only minor conformational changes are seen when these uracil-DNA glycosylase inhibitors bind to their targets (Supplementary Figure S11). All of these uracil-DNA glycosylase inhibitors therefore bind to their targets in conformations that are close to the unbound conformations. As shown in Figure 6, while many of the carboxyl groups on the side chains of SAUGI and UGI share similar locations, most of the carboxyl groups on the side chains of p56 occupy different locations. The matching carboxyl groups on SAUGI and UGI surround the hydrophobic pockets that are used to bind to SAUDG Leu184 and E. coli UDG Leu191, respectively, and they may be functionally important for these two uracil-DNA glycosylase inhibitors.

At this time, the biological meaning of SAUGI remains unclear. In particular, why would Staphylococcus produce a protein that inhibits its own DNA repair system? One possible explanation is as follows. It has recently been shown that the replication of DNA viruses can be blocked by increasing the amount of dUTP in the viral genome (42). Many viruses, such as poxviruses, HSV and retroviruses, encode dUTPase and/or UDG to prevent genomic uracilation (43), while HIV-1 virus also avoids uracilation of its genome by recruiting human UDG (44,45). Meanwhile, among the 27 bacteriophages that infect Staphylococcus, genomic information shows that 13 of them encode dUTPase (46). This suggests that these Staphylococcus phages are sensitive to genomic uracilation. By inhibiting UDG activity and thus preventing the removal of spontaneously deaminated cytosine from phage DNA, SAUGI may act as an anti-phage factor in Staphylococcus. However, this hypothesis still needs to be verified, and other roles for SAUGI are also possible. For example, SAUGI may simply act as a regulator that modulates the SAUDG activity in Staphylococcus. As a first step in exploring this possibility, it would be interesting to observe the effects of up- or downregulation of SAUGI expression in Staphylococcus.

While the high binding affinity of UGI to human UDG might be cytotoxic to human cells, we note that SAUGI’s relatively low binding affinity to human UDG (Supplementary Figure S10 and Table 3) might allow it to directly suppress UDG repair activity in S. aureus and other human pathogens. In addition, SAUGI-based drugs might be used to decrease the replication of viruses such as HSV by inhibiting their UDG activity. Lastly, the His-pulldown assay showed that SAUGI interacted with other DNA binding proteins in addition to SAUDG (Supplementary Figure S4 and Supplementary Table S3), and we have further confirmed the interaction between SAUGI and the SALEX transcription factor (LexA) using a bis (sulphosuccinimidyl) suberate (BS3) cross-linking assay (Supplementary Figure S12). These results suggest that SAUGI may also act to regulate other DNA binding proteins.

In conclusion, this is the first case of a DNA mimic protein identified by using a bioinformatic approach, and it also represents the first uracil-DNA glycosylase inhibitor from a non-phage species.
ACKNOWLEDGEMENTS

The authors are grateful to the staff of beamline BL13B1 at the Radiation Research Center (NSRRC) in Hsinchu, Taiwan, for their help in X-ray crystal data collection. They also thank the Core Facilities for Proteomics Research located at the Institute of Biological Chemistry, Academia Sinica, for their help in Proteomic mass spectrometry analyses.

FUNDING

This work was supported financially by Academia Sinica, Taipei Medical University and National Science Council [022371, TMU102-AE1-B12 and NSC102-2319-B-001-003]. Funding for open access charge: Academia Sinica and National Science Council [022371 and NSC102-2319-B-001-003].

Conflict of interest statement. None declared.

REFERENCES